心脈醫療(688016.SH)新增全資子公司上海鴻脈為募投項目實施主體
格隆匯12月11日丨心脈醫療(688016.SH)公佈,公司擬增加上海鴻脈醫療科技有限公司作為主動脈及外周血管介入醫療器械研究開發項目實施主體,並使用部分募集資金5000萬元對公司全資子公司上海鴻脈進行增資,本次增資5000萬元全部計入上海鴻脈的註冊資本。
公司主動脈及外周血管介入醫療器械研究開發項目涉及7項主動脈介入醫療器械和11項外周血管介入醫療器械的研究開發。通過實施本募投項目,公司可以進一步完善現有主動脈和外周產品線,鞏固市場地位,增強抗風險能力,開闢新的增長驅動力及盈利增長點,從而進一步擴大公司在主動脈及外周血管介入醫療器械的市場份額及品牌影響力。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.